What does pharmacovigilance earn in DACH pharma 2026?
Pharmacovigilance pays from junior PV specialist (€55,000–70,000) to EU QPPV and head of PV (€180,000–240,000). Specialisations: case processing (ICSR, MedDRA coding), signal detection, aggregate reporting (PSUR, PBRER, DSUR), risk management plans (RMP), EU QPPV function. CROs (ICON, IQVIA, Parexel, Syneos Health, Labcorp, Fortrea, PPD, Medpace) are the most open employers for 100% remote — pharmacovigilance is the pharma function most easily remote-capable with the largest vacancy pool.
What pharmacovigilance in pharma actually does
Pharmacovigilance (PV, drug safety) is responsible for the continuous collection, assessment, and reporting of adverse drug reactions across a drug's entire lifecycle. Core activities: individual case safety reports (ICSR) intake and triage, MedDRA coding, severity assessment, causality assessment, submission to EVDAS (EudraVigilance Data Analysis System). Signal detection using statistical methods (PRR, ROR, EBGM in EMA EudraVigilance). Aggregate reporting: periodic safety update reports (PSUR), periodic benefit-risk evaluation reports (PBRER), development safety update reports (DSUR), risk management plans (RMP), post-authorisation safety studies (PASS). EU qualified person for pharmacovigilance (EU QPPV) is the regulatory-mandatory function with 24/7 responsibility.
Who hires pharmacovigilance in DACH
CROs are the most open and largest pharmacovigilance employers in DACH with 100% remote as the default: ICON, IQVIA, Parexel, Syneos Health, Labcorp Drug Development, Fortrea, PPD (Thermo Fisher), Medpace, Worldwide Clinical Trials, Premier Research, ProPharma Group, BlueClinical, KCR. Big Pharma sponsor: Bayer (Berlin, Wuppertal), Roche (Basel), Novartis (Basel), Pfizer Germany (Berlin), Boehringer Ingelheim (Ingelheim), AstraZeneca (Wedel), GSK (Munich), Merck KGaA (Darmstadt), Sanofi (Frankfurt), Janssen (Neuss), Lilly (Bad Homburg), MSD (Haar), BMS (Munich), AbbVie (Wiesbaden), Daiichi Sankyo (Munich). Specialty biotech: BioNTech, Curevac, Vertex, BioMarin, Alnylam, Moderna. Generics: Stada, Hexal/Sandoz, Ratiopharm, Mylan/Viatris. Standalone PV service providers: ProductLife Group, ClinChoice, Voisin Consulting.
Pharmacovigilance salary bands DACH 2026
Junior PV specialist (case processing) €55,000–70,000, PV specialist II €70,000–85,000, senior PV specialist €85,000–105,000. PV manager (aggregate reports, signal detection) €105,000–130,000, senior PV manager €130,000–160,000. Local QPPV (EU member state) €130,000–160,000. EU QPPV €160,000–220,000 (24/7 responsibility). Head of drug safety / head of PV €180,000–240,000. Global head of pharmacovigilance €230,000–320,000+. Specialty indications (oncology, ATMP, rare disease) pay 10–15% premium. Remote contracts at CROs are the standard; pay 5–10% below office level for generalist skills, at level for specialty expertise.
The hidden pharmacovigilance job market
Case processing roles (junior to senior PV specialist) are 70–80% visible via LinkedIn, CRO career portals, PharmiWeb, PV society job boards. PV manager and senior PV manager are 50–60% hidden — specialist headhunters (Real Staffing PV, Hays Life Sciences PV, ProClinical PV, Cobalt Recruitment) and direct LinkedIn outreach. Local QPPV, EU QPPV, and head of PV are 80–90% hidden — Egon Zehnder, Russell Reynolds, Heidrick & Struggles for senior executive search. ATMP, oncology, and rare disease have the highest hidden share.
Pharmacovigilance career paths in DACH
Standard path: junior PV specialist (1–2 years case processing) → PV specialist II (2–3 years) → senior PV specialist (2–3 years, taking on aggregate reports and signal detection) → PV manager (3–5 years) → senior PV manager or local QPPV → EU QPPV or head of PV. Specialisation in signal detection with statistical depth, in aggregate reporting (PSUR medical writing), or in specialty indications determines pay and pace. CRO ↔ sponsor moves are standard. EU QPPV typically requires a pharmacy degree plus 5–10 years of PV experience. My Reverse Recruitment helps place EU QPPV career moves or ATMP specialty pivots precisely.
Frequently asked questions
Is pharmacovigilance 2026 truly 100% remote-capable in DACH?
Yes, especially at CROs (ICON, IQVIA, Parexel, Syneos, Labcorp, Fortrea, PPD, Medpace) — case processing, signal detection, and aggregate reporting are placed remote by default. Big Pharma sponsor has predominantly introduced hybrid policies since 2024 (2–3 days office), but still offers remote for rare specialty expertise and for employees who have been remote since pre-COVID.
What qualifications do I need for pharmacovigilance?
For junior PV specialist and case processing, a bachelor's or master's in pharmacy, biology, chemistry, medicine, or related life sciences is sufficient. Senior PV and manager roles often require a master's or doctorate. EU QPPV function requires under EU GVP a pharmacy degree plus 5–10 years of demonstrable PV experience. MedDRA coding certification and EU CTR / EVDAS knowledge are standard expectations in 2026.
Which PV specialisation pays best in DACH 2026?
EU QPPV (€160,000–220,000) and head of drug safety (€180,000–240,000) are the best-paid PV roles. Signal detection with statistical depth (PRR/ROR/EBGM, R/SAS programming) and ATMP PV (gene, cell therapy) pay 10–15% premium. Specialty pharmacovigilance in oncology and rare disease with 5+ years of experience reaches €140,000–180,000.